Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - efficient
4
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...
Published: 10/28/2024
|
Inventor(s):
Stephen Leppla
,
Shihui Liu
,
Thomas Bugge
,
Diane Peters
,
Jie Liu
,
Alexander Wein
,
Kuang-Hua Chen
,
Christopher Bachran
,
Damilola Phillips
,
Henning Hansen
,
Sarah Arnett
,
Clinton Leysath
Keywords(s):
Against
,
AMOUNTS
,
Anthrax
,
AnthraxToxins
,
ANTIGEN
,
B
,
CA1BXX
,
CB1AXX
,
CB1BXX
,
CB1XXX
,
CB3CXX
,
CBXXXX
,
Cells
,
Cell-Surface
,
CMG2
,
COMPLEMENTARY
,
CONTAIN
,
Containing
,
CXXXXX
,
Cytolethal
,
Distending
,
EFFICACY
,
Efficient
,
ENGINEERED
,
exclusively
,
Exploiting
,
FELINE
,
FELINE Leukemia
,
FORM
,
Fusion
,
fusion proteins
,
Having
,
High
,
IC2-PA
,
Identifying
,
Improved
,
Leppla
,
Listed LPM McCue as of 4/15/2015
,
MARKER
,
Metallo...
,
MULTIMERIC
,
Mutated
,
Nature
,
Octamers
,
Patent Category - Biotechnology
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
Protective
,
Protein
,
proteins
,
SOLID
,
SPECIFICALLY
,
Specificity
,
Strong
,
TARGET
,
Targeting
,
That
,
THERAPY
,
toxin
,
TOXINS
,
tumor
,
Types
,
UAXXXX
,
VARIANTS
,
VASCULATURE
,
VETERINARY
Category(s):
Collaboration Sought > Collaboration
,
Application > Therapeutics
,
TherapeuticArea > Oncology
,
TherapeuticArea > Immunology
,
Application > Diagnostics
,
TherapeuticArea > Rare / Neglected Diseases
Humanized Monoclonal Antibodies
Efficient
for Neutralization of Tick-Borne Encephalitis Virus (TBEV)
TBEV causes serious illnesses from meningitis to meningo-encephalitis, totaling 3,000 cases of hospitalization in Europe and between 5,000-10,000 cases in Russia reported every year. The Far Eastern hemorrhagic TBEV strains are associated with a mortality rate (between 1-2%), higher than other strains isolated in the Siberia or Western Europe. There...
Published: 10/28/2024
|
Inventor(s):
Alexander Pletnev
,
Ching-juh Lai
,
Robert Purcell
Keywords(s):
antibodies
,
ANTIBODY
,
Binding/Neutralization
,
Chimpanzee
,
DA4BXX
,
DA4XXX
,
DAXXXX
,
DB4BXX
,
DB4XXX
,
DBXXXX
,
DDXXXX
,
DERIVED
,
DXXXXX
,
Efficient
,
ENCEPHALITIS
,
FAB
,
Fragments
,
HUMANIZED
,
monoclonal
,
TBEV
,
TICK-BORNE
,
virus
Category(s):
Collaboration Sought > Collaboration
,
Application > Diagnostics
,
Application > Research Materials
,
Application > Therapeutics
,
TherapeuticArea > Infectious Disease
Humanized Monoclonal Antibodies that Specifically Bind Japanese Encephalitis Virus (JEV) and Their Use
Japanese encephalitis virus (JEV) is the prototype virus of the Japanese encephalitis (JE) group belonging to the Flavivirus genus of the Flaviviridae family. Other members of the group include Kunjin virus, St. Louis encephalitis virus, and West Nile encephalitis virus (WNV). JEV is widely distributed in South Asia, Southeast Asia, and the Asian Pacific...
Published: 10/28/2024
|
Inventor(s):
Robert Purcell
,
Ching-juh Lai
,
Ana Goncalvez
Keywords(s):
Against
,
antibodies
,
BBXXXX
,
Chimpanezee
,
DA4BXX
,
DA4XXX
,
DAXXXX
,
DB4XXX
,
DBXXXX
,
DC5XXX
,
DCXXXX
,
DDXXXX
,
DERIVED
,
DXXXXX
,
Efficient
,
Fabs
,
HUMANIZED
,
Infection
,
JAPANESE
,
Japanese encephalitis
,
JEV
,
Mice
,
monoclonal
,
Neutralization
,
Patent Category - Biotechnology
,
Protection
,
virus
,
Vitro
Category(s):
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
Application > Therapeutics
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
,
Application > Diagnostics
,
Application > Vaccines
Vaccines Comprising Sand Fly Salivary Proteins for Control of Leishmania Infection
This invention relates to the use of several peptides from the salivary glands of various sand fly species for the control of leishmania infection. Many of these peptides were shown to be effective in eliciting potent immune responses in animal models and are excellent candidates for the development of vaccines against the disease. A vaccine comprising...
Published: 10/28/2024
|
Inventor(s):
Jesus Valenzuela
Keywords(s):
Adn
,
America
,
ARIASI
,
Cellular
,
Chagase
,
DA2XXX
,
DAXXXX
,
DB2XXX
,
DBXXXX
,
DC2XXX
,
DCXXXX
,
DDXXXX
,
Dogs
,
DXXXXX
,
Efficient
,
ELICIT
,
Fly
,
Identification
,
IFN-gamma
,
Immunity
,
Infantum
,
KILLING
,
Latin
,
LEISHMANIA
,
LEISHMANIASIS
,
Leishmaniasis (Leishmania sp.)
,
Listed LPM Stansberry as of 4/15/2015
,
LJL143
,
LJM17
,
Longipalpis
,
Lutzomyiz
,
Method
,
P.
,
Patent Category - Biotechnology
,
PERNICIOSUS
,
POLYPEPTIDES
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
production
,
proteins
,
RESULTING
,
Salivary
,
SAND
,
That
,
Vector
,
Visceral
,
WIPO Re:search
Category(s):
Collaboration Sought > Collaboration
,
Application > Research Materials
,
Application > Diagnostics
,
Application > Therapeutics
,
Application > Vaccines
,
TherapeuticArea > Infectious Disease